Antagonist Protocol in IVF

Phase 2

• Conditions: Infertility
• Interventions: Drug: Gonadotropins releasing hormone antagonist

• Registration Number: NCT02335736
• Lead Sponsor: Woman's Health University Hospital, Egypt

Brief Summary

The antagonist protocol in a novel method of stimulation in the in vitro fertilization (IVF) patients. It has been tried in poor responders, polycystic ovary (PCO) patients and normal females undergoing IVF. Can it be used with the same efficacy in all patients?

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01
• Study First Submitted: 2015-01-07
• Study First Submitted QC: 2015-01-09
• Study First Posted: 2015-01-12
• Primary Completion: 2015-08
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-12
• Last Update Posted: 2016-02-15
• Study Completion: 2016-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

• age: 20- 44 years
• Poor responder females according to Bologna criteria
• Polycystic ovarian disease females according to Rotterdam criteria
• Females with infertility causes other than poor responders, or PCO; male factor or tubal block

Exclusion Criteria

• refusal to get enrolled in the study
• cases of infertility due to severe male factor

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Normal	Gonadotropins releasing hormone antagonist	Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
Poor responders	Gonadotropins releasing hormone antagonist	Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
Polycystic ovarian disease	Gonadotropins releasing hormone antagonist	Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC

Primary Outcome Measures

Name	Time	Method
number of oocytes collected and fertilized	6 months

Trial Locations

Locations (1)

Kasr el aini hospital; 🇪🇬 Cairo, Egypt